This observational study was planned, with the primary objective to observe patient survival following first-line treatment of patients of Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) with different platinum-based doublets under routine disease management conditions. Further secondary objectives of this study are to provide insights to what extent histologic subtyping and the use of additional prognostic or predictive biomarkers are currently considered for differential therapeutic decisions under routine conditions. All of these data are critical to evaluate the factors for differential therapeutic decisions and their effect on patient outcomes in a real life setting, and they can only be obtained through observational research.
Study Type
OBSERVATIONAL
Enrollment
1,610
Dosage, dosage form, frequency and duration according to daily hospital practice
Overall survival
Time frame: Treatment start to death from any cause (follow-up assessments until death or until end of study, up to 18 months from Last Patient Entered Treatment)
One-year survival rate
Time frame: 12 months
Progression-free survival
Time frame: Treatment start to progression or death (follow-up assessments until death or until end of study, up to 18 months from Last Patient Entered Treatment)
Best tumor response
Time frame: Treatment start to progression or treatment end
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.